You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 3
  • #435 Changes of lifestyle, exercise of precaution and preferences – interim results of an international survey for endometrial cancer patients (NOGGO, ENGOT, GCIG – expression XI/IMPROVE)

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
03. Endometrial cancer
#435 Changes of lifestyle, exercise of precaution and preferences – interim results of an international survey for endometrial cancer patients (NOGGO, ENGOT, GCIG – expression XI/IMPROVE)
Free
  1. Lukas Chinczewski1,
  2. Catherine Krause1,
  3. Dario Zocholl2,
  4. Jolijn Boer3,
  5. Flurina Saner4,5,
  6. Clemens Liebrich6,
  7. Daniela Luminita Zob7,
  8. Tibor Zwimpfer8,5,
  9. Cristin Kühn9,
  10. Ralf Rothmund10,5,
  11. Adelina Silvana Gheorghe7,11,
  12. Mustafa Celalettin Ugur12,
  13. Michael Müller4,5,
  14. Julia Klenske13,
  15. Viola Heinzelmann-Schwarz8,5,
  16. Nicole Stahl14,
  17. Martin Heubner15,5,
  18. Maren Keller3 and
  19. Jalid Sehouli1,3
  1. 1Department of Gynecology with Center for Oncological Surgery – Charité – Universitätsmedizin Berlin, Berlin, Germany
  2. 2Institute of Biometry and Clinical Epidemiology – Charité – Universitätsmedizin Berlin – corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
  3. 3Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO e.V.), Berlin, Germany
  4. 4University Hospital of Bern, Bern, Switzerland
  5. 5Swiss GO Trial Group, Basel, Switzerland
  6. 6Klinikum Wolfsburg – Frauenklinik, Wolfsburg, Germany
  7. 7Institute of Oncology Prof. Dr. Al. Trestioreanu, Bucharest, Romania
  8. 8University Hospital of Basel, Basel, Switzerland
  9. 9Christliches Klinikum Unna, Unna, Germany
  10. 10Lindenhofspital, Basel, Switzerland
  11. 11University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
  12. 12Agaplesion Diakonieklinikum Hamburg, Hamburg, Germany
  13. 13Zollernalb Klinikum, Balingen, Germany
  14. 14Helios Klinikum Schwerin, Schwerin, Germany
  15. 15Kantonsspital Baden, Baden, Switzerland

Abstract

Introduction/Background Endometrial cancer (EC) is commonly associated with cardiovascular risk factors such as obesity and metabolic diseases. Especially in type 1 cancer, strong correlation with these characteristics was demonstrated. For successful holistic conduction of therapy, the patient’s wish for change and compliance must be understood better. The aim of this study was to define the status quo of patient needs and preferences.

Methodology An 80 item survey in paper-form and via internet was distributed to patients with diagnosed EC in seven countries. General patient characteristics (comorbidities, tumor stage, therapy), monitoring of lifestyle before and after diagnosis and adherence to treatment modalities were recorded.

Results Between 12/2021 and 04/2023, 656 patients with EC (median age: 65.0[20.0; 92.0] years) completed the survey. Major recruitment took place in Germany (56%) and Switzerland (41%). The most common comorbidities were hypertension (42%), diabetes (13%) and hypothyroidism (20%). 46% of patients reported not exercising before diagnosis of EC. Only 14% increased their activity after diagnosis, 39% did even less (49% of those due to weakness). The need for medical exercise programs was low – only 30% were interested - although 55% felt that more activity would benefit their disease. 62% reported that they had not changed their diet after diagnosis. 31% would be interested in a professional nutrition counseling program, 81% did not receive one during treatment. Regarding screening programs, 52% participated in the colonoscopy program, 61% in the cervical cancer program, 34% in the skin cancer program and 71% in mammography screening.

Conclusion A majority of patients believe in a potential positive impact of lifestyle changes, such as exercising and diets. Nevertheless, physical activity appeared to be relatively low and most patients did not change their diet after diagnosis. There is a need for better support of patients in these aspects, to achieve the known benefits of holistic treatment.

Disclosures Financial support by GlaxoSmithKline Research & Development Limited.

https://doi.org/10.1136/ijgc-2023-ESGO.328

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.